Abstract
Introduction: Balloon pulmonary angioplasty (BPA) is an effective intervention for patients with chronic thromboembolic pulmonary disease (CTEPD). We aimed to identify the patient group with a low success rate or high complication rate of BPA, which is still unclear. Methods: Both CTEPD patients with or without pulmonary hypertension (CTEPH and NoPH-CTEPD) were included. CTEPH patients were divided into groups with or without pulmonary endarterectomy (PEA-CTEPH and NoPEA-CTEPH). The efficacy and safety of BPA were compared among the groups. Results: There were 450, 66, and 41 sessions in the NoPEA-CTEPH, PEA-CTEPH, and NoPH-CTEPD groups, respectively. The success rate (≥1 degree improvement in flow grade) in the PEA-CTEPH group was 94.5%, significantly lower than that in the NoPEA-CTEPH (97.1%) and NoPH-CTEPD (98.4%) groups (p = 0.014). The percentage of complete flow recovery in treated vessels was also lower in PEA-CTEPH group. BPA-related complication rate in NoPEA-CTEPH, PEA-CTEPH, and NoPH-CTEPD patients was 6.1%, 6.0%, and 0.0%, respectively (p = 0.309). One BPA-related death occurred (solely in NoPEA-CTEPH). Mean pulmonary artery pressure ≥41.5 mm Hg was a predictor of BPA-related complications. NoPEA-CTEPH patients had more improvement in 6-min walk distance (6MWD, 87 ± 93 m NoPEA-CTEPH vs. 40 ± 43 m PEA-CTEPH vs. 18 ± 20 m NoPH-CTEPD, p = 0.012). Conclusions: BPA was safe and effective for all CTEPD groups with less improvement for the PEA-CTEPH and NoPH-CTEPD groups. The success rate of BPA was lower in the PEA-CTEPH group and the complication rate was lower in the NoPH-CTEPD group. Pre-BPA treatment to lower pulmonary artery pressure should not be overlooked in CTEPD patients.
References
1.
Fernandes
T
, Planquette
B
, Sanchez
O
, Morris
T
. From acute to chronic thromboembolic disease
. Ann Am Thorac Soc
. 2016
;13
(Suppl 3
):S207
–214
. 2.
Nakano
Y
, Adachi
S
, Nishiyama
I
, Yasuda
K
, Imai
R
, Yoshida
M
, et al. Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: the Nagoya PE study
. J Thromb Haemost
. 2022
;20
(4
):888
–98
. 3.
Becattini
C
, Agnelli
G
, Pesavento
R
, Silingardi
M
, Poggio
R
, Taliani
MR
, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism
. Chest
. 2006
;130
(1
):172
–5
. 4.
Delcroix
M
, Torbicki
A
, Gopalan
D
, Sitbon
O
, Klok
FA
, Lang
I
, et al. ERS statement on chronic thromboembolic pulmonary hypertension
. Eur Respir J
. 2021
;57
(6
):2002828
. 5.
Delcroix
M
, Lang
I
, Pepke-Zaba
J
, Jansa
P
, D’Armini
AM
, Snijder
R
, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry
. Circulation
. 2016
;133
(9
):859
–71
. 6.
Zhang
L
, Bai
Y
, Yan
P
, He
T
, Liu
B
, Wu
S
, et al. Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis
. Heart Fail Rev
. 2021
;26
(4
):897
–917
. 7.
Yanaka
K
, Nakayama
K
, Shinke
T
, Shinkura
Y
, Taniguchi
Y
, Kinutani
H
, et al. Sequential hybrid therapy with pulmonary endarterectomy and additional balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
. J Am Heart Assoc
. 2018
;7
(13
):e008838
. 8.
Claeys
M
, Claessen
G
, La Gerche
A
, Petit
T
, Belge
C
, Meyns
B
, et al. Impaired cardiac reserve and abnormal vascular load limit Exercise capacity in chronic thromboembolic disease
. JACC Cardiovasc Imaging
. 2019
;12
(8 Pt 1
):1444
–56
. 9.
Inami
T
, Kataoka
M
, Kikuchi
H
, Goda
A
, Satoh
T
. Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest
. Int J Cardiol
. 2019
;289
:116
–8
. 10.
Wiedenroth
CB
, Deissner
H
, Adameit
MSD
, Kriechbaum
SD
, Ghofrani
HA
, Breithecker
A
, et al. Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: impact on the outcome
. J Heart Lung Transpl
. 2022
;41
(8
):1086
–94
. 11.
Wiedenroth
CB
, Olsson
KM
, Guth
S
, Breithecker
A
, Haas
M
, Kamp
JC
, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease
. Pulm Circ
. 2018
;8
(1
):2045893217753122
. 12.
Kawakami
T
, Ogawa
A
, Miyaji
K
, Mizoguchi
H
, Shimokawahara
H
, Naito
T
, et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty
. Circ Cardiovasc Interv
. 2016
;9
(10
):e003318
. 13.
Inami
T
, Kataoka
M
, Shimura
N
, Ishiguro
H
, Yanagisawa
R
, Taguchi
H
, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty
. JACC Cardiovasc Interv
. 2013
;6
(7
):725
–36
. 14.
Ejiri
K
, Ogawa
A
, Fujii
S
, Ito
H
, Matsubara
H
. Vascular injury is a major cause of lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension
. Circ Cardiovasc Interv
. 2018
;11
(12
):e005884
. 15.
Mizoguchi
H
, Ogawa
A
, Munemasa
M
, Mikouchi
H
, Ito
H
, Matsubara
H
. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension
. Circ Cardiovasc Interv
. 2012
;5
(6
):748
–55
. 16.
Kawakami
T
, Matsubara
H
, Shinke
T
, Abe
K
, Kohsaka
S
, Hosokawa
K
, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial
. Lancet Respir Med
. 2022
;10
(10
):949
–60
. 17.
Lang
IM
, Andreassen
AK
, Andersen
A
, Bouvaist
H
, Coghlan
G
, Escribano-Subias
P
, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function
. Eur Heart J
. 2023
;44
(29
):2659
–71
. 18.
Sugimoto
K
, Nakazato
K
, Sakamoto
N
, Yamaki
T
, Kunii
H
, Yoshihisa
A
, et al. Pulmonary artery diameter predicts lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension
. Int Heart J
. 2017
;58
(4
):584
–8
. 19.
Shimokawahara
H
, Nagayoshi
S
, Ogawa
A
, Matsubara
H
. Continual improvement in pressure gradient at the lesion after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
. Can J Cardiol
. 2021
;37
(8
):1232
–9
. 20.
Takigami
M
, Nakanishi
N
, Tsubata
H
, Fukai
K
, Matsubara
Y
, Yanishi
K
, et al. Efficacy and safety of guide extension catheter in balloon pulmonary angioplasty for treatment of complex lesions in chronic thromboembolic pulmonary hypertension
. PLoS One
. 2023
;18
(1
):e0280683
. 21.
Ito
R
, Yamashita
J
, Sasaki
Y
, Ikeda
S
, Suzuki
S
, Murata
N
, et al. Efficacy and safety of balloon pulmonary angioplasty for residual pulmonary hypertension after pulmonary endarterectomy
. Int J Cardiol
. 2021
;334
:105
–9
. 22.
Hug
KP
, Gerry Coghlan
J
, Cannon
J
, Taboada
D
, Toshner
M
, Sheares
K
, et al. Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment
. J Heart Lung Transpl
. 2021
;40
(10
):1223
–34
. 23.
Mayer
E
, Jenkins
D
, Lindner
J
, D’Armini
A
, Kloek
J
, Meyns
B
, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry
. J Thorac Cardiovasc Surg
. 2011
;141
(3
):702
–10
. 24.
Roik
M
, Wretowski
D
, Łabyk
A
, Kostrubiec
M
, Irzyk
K
, Dzikowska-Diduch
O
, et al. Refined balloon pulmonary angioplasty driven by combined assessment of intra-arterial anatomy and physiology: Multimodal approach to treated lesions in patients with non-operable distal chronic thromboembolic pulmonary hypertension--Technique, safety and efficacy of 50 consecutive angioplasties
. Int J Cardiol
. 2016
;203
:228
–35
. 25.
Araszkiewicz
A
, Darocha
S
, Pietrasik
A
, Pietura
R
, Jankiewicz
S
, Banaszkiewicz
M
, et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy
. Int J Cardiol
. 2019
;278
:232
–7
. 26.
Brenot
P
, Jaïs
X
, Taniguchi
Y
, Garcia Alonso
C
, Gerardin
B
, Mussot
S
, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
. Eur Respir J
. 2019
;53
(5
):1802095
. 27.
Higuchi
S
, Horinouchi
H
, Aoki
T
, Nishii
T
, Ota
Y
, Ueda
J
, et al. Balloon pulmonary angioplasty in the management of chronic thromboembolic pulmonary hypertension
. Radiographics
. 2022
;42
(6
):1881
–96
. 28.
de Perrot
M
, Gopalan
D
, Jenkins
D
, Lang
IM
, Fadel
E
, Delcroix
M
, et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension: consensus statement from the ISHLT
. J Heart Lung Transplant
. 2021
;40
(11
):1301
–26
. 29.
Jaïs
X
, Brenot
P
, Bouvaist
H
, Jevnikar
M
, Canuet
M
, Chabanne
C
, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study
. Lancet Respir Med
. 2022
;10
(10
):961
–71
. 30.
Kennedy
MK
, Kennedy
SA
, Tan
KT
, de Perrot
M
, Bassett
P
, McInnis
MC
, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis
. Cardiovasc Intervent Radiol
. 2023
;46
(1
):5
–18
. 31.
Kinutani
H
, Shinke
T
, Nakayama
K
, Taniguchi
Y
, Otake
H
, Takaya
T
, et al. High perfusion pressure as a predictor of reperfusion pulmonary injury after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
. Int J Cardiol Heart Vasculature
. 2016
;11
:1
–6
. 32.
Jain
N
, Sheikh
MA
, Bajaj
D
, Townsend
W
, Krasuski
R
, Secemsky
E
, et al. Periprocedural complications with balloon pulmonary angioplasty: analysis of global studies
. JACC Cardiovasc Interv
. 2023
;16
(8
):976
–83
. 33.
Humbert
M
, Kovacs
G
, Hoeper
MM
, Badagliacca
R
, Berger
RMF
, Brida
M
, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
. Eur Heart J
. 2023
;61
(1
):2200879
. 34.
Darocha
S
, Araszkiewicz
A
, Kurzyna
M
, Banaszkiewicz
M
, Jankiewicz
S
, Dobosiewicz
A
, et al. Balloon pulmonary angioplasty in technically operable and technically inoperable chronic thromboembolic pulmonary hypertension
. J Clin Med
. 2021
;10
(5
):1038
. 35.
Minatsuki
S
, Kiyosue
A
, Kodera
S
, Hara
T
, Saito
A
, Maki
H
, et al. Effectiveness of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension despite having lesion types suitable for surgical treatment
. J Cardiol
. 2020
;75
(2
):182
–8
. 36.
Darocha
S
, Banaszkiewicz
M
, Pietrasik
A
, Siennicka
A
, Piorunek
M
, Grochowska
E
, et al. Changes in estimated glomerular filtration after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
. Cardiorenal Med
. 2020
;10
(1
):22
–31
. 37.
Eng
J
, Wilson
RF
, Subramaniam
RM
, Zhang
A
, Suarez-Cuervo
C
, Turban
S
, et al. Comparative effect of contrast media type on the incidence of contrast-induced nephropathy: a systematic review and meta-analysis
. Ann Intern Med
. 2016
;164
(6
):417
–24
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
